Press release
Non-Alcoholic Steatohepatitis (NASH) Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers
Non Alcoholic Steatohepatitis NASH Market
The growth demand for the non-alcoholic steatohepatitis (NASH) market is being spurred by an increase in obesity cases. Obesity, characterized by excessive fat accumulation and body weight above the expected health standard for a specific height, is a major health concern. The rise in non-alcoholic fatty liver disease prevalence, driven by the growing obesity epidemic, is likely to make NASH the leading cause of critical liver disease in the coming years, thus fueling the NASH market growth for treatment and associated medications. In particular, data from the World Health Organization (WHO), a UK-based global public health entity, showed that in 2022, around 2.5 billion adults over 18 years were overweight, with 890 million battling obesity as of March 2024. Consequently, the increase in obesity cases will continue to influence the non-alcoholic steatohepatitis (NASH) market's expansion.
Get Your Non-Alcoholic Steatohepatitis (NASH) Market Report Here:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report
What is the future CAGR of the non-alcoholic steatohepatitis (nash) market, and how will it impact industry expansion?
Recent years have seen a substantial growth in the market size of non-alcoholic steatohepatitis (NASH). Projections show that it will expand from a market value of $4.5 billion in 2024 to $6.13 billion the following year, indicating a compound annual growth rate (CAGR) of 36.1%. The growth observed during the historical period can be linked to a higher prevalence of NASH, an obesity crisis, increased awareness and diagnoses, changing lifestyle and dietary trends, and improvements in the healthcare infrastructure.
The market size for non-alcoholic steatohepatitis (NASH) is projected to experience significant expansion in the coming years. Its size is forecasted to reach $19.07 billion by 2029, with a compound annual growth rate (CAGR) of 32.8%. This growth in the projected period is credited to developments in NASH drugs, the escalation of NASH screening programs, increased healthcare spending, joint research endeavors, and governmental assistance and regulations. The upcoming period also indicates notable trends such as emphasis on lifestyle changes and patient awareness, enhanced partnerships in clinical studies, advances in regulatory measures and pathway designations, and the application of artificial intelligence for diagnosis and monitoring.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp
How are the latest trends influencing the growth of the non-alcoholic steatohepatitis (nash) market?
Key players in the non-alcoholic steatohepatitis (NASH) market are focusing on the creation of thyroid hormone receptor-beta (THR-beta) agonists. These act to stimulate liver metabolism, limit the buildup of fat in the liver, and optimize liver functionality. THR-beta agonists are a type of compound that selectively trigger the thyroid hormone receptor-beta subtype, a crucial receptor for handling metabolism, growth, and development. For example, Rezdiffra (resmetirom), a THR-beta agonist, was given approval by the US Food and Drug Administration in March 2024 as the inaugural treatment intended for adults suffering from noncirrhotic NASH with medium to severe liver fibrosis. Through selectively triggering the THR-beta receptor, Rezdiffra regulates lipid metabolism, causing a decline in intrahepatic triglycerides and total liver fat accumulation.
What are the major segments of the non-alcoholic steatohepatitis (nash) market and their role in driving growth?
The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented -
1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805
Which regions are key players in the growth of the non-alcoholic steatohepatitis (nash) market?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the key firms paving the way for growth in the non-alcoholic steatohepatitis (nash) market?
Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp
What Is Covered In The Non-Alcoholic Steatohepatitis (NASH) Global Market Report?
•Market Size Forecast: Examine the non-alcoholic steatohepatitis (nash) market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the non-alcoholic steatohepatitis (nash) market for a structured understanding.
•Key Players Overview: Analyze major players in the non-alcoholic steatohepatitis (nash) market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the non-alcoholic steatohepatitis (nash) market.
•Segment Contributions: Evaluate how different segments drive overall growth in the non-alcoholic steatohepatitis (nash) market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the non-alcoholic steatohepatitis (nash) market.
•Industry Challenges: Identify potential risks and obstacles affecting the non-alcoholic steatohepatitis (nash) market.
•Competitive Landscape: Review strategic developments in the non-alcoholic steatohepatitis (nash) market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Steatohepatitis (NASH) Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers here
News-ID: 3911183 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for NASH
The Growing Demand For NASH Treatment Amid Obesity Epidemic: A Key Catalyst Acce …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non-Alcoholic Steatohepatitis (NASH) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for non-alcoholic steatohepatitis (NASH) has seen a considerable expansion in the past few years. Its value is expected to rise from $4.5 billion in 2024 to $6.06 billion in 2025, marking…
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
